Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2024

Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2025 – By Type (Small Molecules, Biologics), By Distribution Channel (Offline, Online), By Application (Hospitals, Clinics, Home Care) – Market Size, Trends, And Global Forecast 2025-2034

Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Definition

duchenne muscular dystrophy (DMD) therapeutics refers to the various medical treatments and interventions aimed at managing and alleviating the symptoms of duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle weakness and degeneration. These therapeutic approaches are designed to slow disease progression, improve muscle function and enhance the overall quality of life for individuals with duchenne muscular dystrophy.

The main types of duchenne muscular dystrophy (DMD) therapeutics are Small Molecules and biologics. Small molecules are low-molecular-weight compounds that can interact with specific proteins or targets in the body and they can be designed to target specific aspects of DMD, such as reducing inflammation, promoting muscle regeneration, or addressing specific genetic mutations. Therapeutics are distributed through offline and online channels for applications in hospitals, clinics and home care.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation

The duchenne muscular dystrophy (DMD) therapeutics market covered in this report is segmented –

1) By Type: Small Molecules, Biologics

2) By Distribution Channel: Offline, Online

3) By Application: Hospitals, Clinics, Home Care

Subsegments:

1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds

2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and growth rate 2025 to 2029: Graph

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size 2025 And Growth Rate

The duchenne muscular dystrophy (DMD) therapeutics market size has grown exponentially in recent years. It will grow from $11.95 billion in 2024 to $16.45 billion in 2025 at a compound annual growth rate (CAGR) of 37.6%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, awareness about duchenne muscular dystrophy treatment, rising healthcare spending, government initiatives.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Forecast

The duchenne muscular dystrophy (DMD) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $47.34 billion in 2029 at a compound annual growth rate (CAGR) of 30.3%. The growth in the forecast period can be attributed to growing investments in for duchenne muscular dystrophy treatments, adoption of combination therapies, emergence of biomarker,growing number of screening programs for duchenne muscular dystrophy. Major trends in the forecast period include innovative treatments for duchenne muscular dystrophy, development of targeted therapies, introduction of novel medications and therapies, innovative disease-modifying therapies, active drug developments.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Driver: Increasing Clinical Trials Revolutionize The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

The rising number of clinical trials is expected to propel the growth of the Duchenne muscular dystrophy (DMD) therapeutics market going forward. Clinical trials are research studies conducted on human participants to evaluate the safety, efficacy and potential benefits of new medical treatments, interventions, or drugs. The surge in clinical trials focusing on Duchenne muscular dystrophy treatment signifies continuous research, innovation and a wide array of therapeutic possibilities, all of which are expected to enhance patient outcomes, attract investments and expedite the advancement and Availability of Effective Therapies for Duchenne Muscular Dystrophy (DMD). For Instance, In August 2023, according to Clinicaltrials.Gov, a part of The National Institutes Of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, the number of registered clinical trials increased to 464,218 compared to 399,496 in 2021 in all 50 states of the United States and across 221 countries. Moreover, IT was reported that 142,700 studies (31% of the total) are registered in the U.S., while 248,310 studies (53% of the total) are recorded in non-U.S. locations. Therefore, a rising number of clinical trials will drive the growth of the duchenne muscular dystrophy (DMD) therapeutics market.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Driver: Expanding Horizons For The Duchenne Muscular Dystrophy (DMD) Market Driven By The Escalating Incidence Of Genetic Disorders

The rising incidence of genetic disorders is anticipated to drive the expansion of the duchenne muscular dystrophy (DMD) market in the future. Genetic disorders refer to a category of medical conditions that result from abnormalities or mutations in an individual's DNA or genetic material. With the increasing occurrence of genetic disorders, a larger population is potentially at risk of DMD due to genetic mutations or familial genetic backgrounds, resulting in greater demand for DMD-related diagnostics, treatments, and therapeutic options. For instance, in February 2022, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, birth abnormalities lead to the deaths of 240,000 newborns in the first 28 days of life annually. Additionally, an extra 170,000 children aged 1 month to 5 years pass away due to birth abnormalities, including heart defects, neural tube defects and Down syndrome. Hence, the increasing prevalence of genetic disorders is propelling the expansion of the Duchenne muscular dystrophy (DMD) market.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Major Players

Major companies operating in the duchenne muscular dystrophy (DMD) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trend: Bit Bio Leads Technological Advancements In Duchenne Muscular Dystrophy (DMD) Therapeutics

Major companies operating in the duchenne muscular dystrophy (DMD) therapeutics market are adopting new technologies to enhance the efficacy and accessibility of treatments for DMD patients and sustain their position in the market. For instance, in July 2023, Bit Bio Ltd., a UK-based synthetic biology company, launched disease model products to advance Duchenne muscular dystrophy (DMD) treatments. The disease models, known as ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes carrying genetically engineered deletions in the gene responsible for dystrophin protein production. Bit. Bio's models, reprogrammed from induced pluripotent stem cells (iPSCs), provide a consistent and scalable source of human cells for research, addressing challenges associated with variability and the sourcing of primary cells. The models support the development of treatments for DMD, offering insights into disease mechanisms and potential therapies. This advancement could accelerate the work of researchers seeking effective treatments for DMD.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Merger And Acquisition: Solid Biosciences Expands Gene Therapy Portfolio With Acquisition Of Aavantibio, Inc. For Duchenne Muscular Dystrophy And Beyond

In December 2022, Solid Biosciences Inc., a US-based biotechnology company, acquired AavantiBio, Inc. for an undisclosed amount. The acquisition enabled Solid Biosciences to expand its portfolio of gene therapy programs for neuromuscular and cardiac diseases, leverage expertise and secure financial resources to advance research, development and potential milestones. AavantiBio, Inc. is a US-based gene therapy company developing transformative treatments for Duchenne muscular dystrophy and other neuromuscular and cardiac diseases.

Regional Outlook For The Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market

North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the duchenne muscular dystrophy (DMD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

What Defines the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?

The duchenne muscular dystrophy (DMD) therapeutics market includes revenues earned by entities by providing services including gene therapies, genetic testing and counseling, telehealth and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The duchenne muscular dystrophy (DMD) therapeutics market also include sales of casimersen, eteplirsen and golodirsen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Duchenne Muscular Dystrophy (DMD) Therapeutics Industry?

The duchenne muscular dystrophy (DMD) therapeutics market research report is one of a series of new reports from The Business Research Company that provides duchenne muscular dystrophy (DMD) therapeutics market statistics, including duchenne muscular dystrophy (DMD) therapeutics industry global market size, regional shares, competitors with a duchenne muscular dystrophy (DMD) therapeutics market share, detailed duchenne muscular dystrophy (DMD) therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the duchenne muscular dystrophy (DMD) therapeutics industry. This duchenne muscular dystrophy (DMD) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $16.45 billion
Revenue Forecast In 2034 $47.34 billion
Growth Rate CAGR of 30.3% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care Subsegments: 1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings plc, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Characteristics

    3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends And Strategies

    4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Analysis And Strategic Analysis Framework

    5.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate Analysis

    5.4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Total Addressable Market (TAM)

    6. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation

    6.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Small Molecules

    Biologics

    6.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Offline

    Online

    6.3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Clinics

    Home Care

    6.4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Exon Skipping Therapies

    Antisense Oligonucleotides

    Read-Through Compounds

    6.5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Gene Therapies

    Cell Therapies

    Protein Replacement Therapies

    7. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Regional And Country Analysis

    7.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    8.1. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    9.1. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    9.2. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    10.1. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    11.1. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    11.2. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    12.1. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    13.1. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    14.1. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    14.2. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    15.1. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    15.2. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    16.1. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    17.1. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    18.1. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    19.1. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    20.1. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    21.1. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    21.2. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    22.1. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    23.1. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    23.2. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    24.1. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    24.2. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    25.1. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    25.2. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    26.1. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    26.2. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    27.1. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    28.1. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    28.2. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    29.1. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

    29.2. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape And Company Profiles

    30.1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape

    30.2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Company Profiles

    30.2.1. CVS Health Corporation Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis

    31. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Other Major And Innovative Companies

    31.1. Otsuka Holdings Co. Ltd.

    31.2. Daiichi Sankyo Co. Ltd.

    31.3. BioMarin Pharmaceutical Inc.

    31.4. Nippon Shinyaku Co. Ltd.

    31.5. CRISPR Therapeutics AG

    31.6. Sarepta Therapeutics Inc.

    31.7. PTC Therapeutics Inc.

    31.8. Halozyme Therapeutics Inc.

    31.9. FibroGen Inc.

    31.10. Exonics Therapeutics Inc.

    31.11. Italfarmaco S.p.A.

    31.12. Wave Life Sciences Ltd.

    31.13. MeiraGTx Holdings plc

    31.14. Editas Medicine Inc.

    31.15. NS Pharma Inc.

    32. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    34. Recent Developments In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

    35. Duchenne Muscular Dystrophy (DMD) Therapeutics Market High Potential Countries, Segments and Strategies

    35.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2029 - Countries Offering Most New Opportunities

    35.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2029 - Segments Offering Most New Opportunities

    35.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Asia-Pacific, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: China, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: India, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Japan, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Australia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Indonesia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: South Korea, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Western Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: UK, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Germany, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: France, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Italy, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Spain, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Eastern Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Russia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: North America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: USA, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Canada, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: South America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Brazil, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Middle East, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Africa, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: CVS Health Corporation Financial Performance
  • Table 77: Pfizer Inc. Financial Performance
  • Table 78: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 79: Bristol-Myers Squibb Company Financial Performance
  • Table 80: Eli Lilly and Co. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Asia-Pacific, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: China, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: India, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Japan, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Australia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Indonesia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: South Korea, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Western Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: UK, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Germany, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: France, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Italy, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Spain, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Eastern Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Russia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: North America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: USA, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Canada, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: South America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Brazil, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Middle East, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Africa, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: CVS Health Corporation Financial Performance
  • Figure 77: Pfizer Inc. Financial Performance
  • Figure 78: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 79: Bristol-Myers Squibb Company Financial Performance
  • Figure 80: Eli Lilly and Co. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Duchenne Muscular Dystrophy (DMD) Therapeutics market?

Duchenne muscular dystrophy (DMD) therapeutics refers to the various medical treatments and interventions aimed at managing and alleviating the symptoms of duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle weakness and degeneration. These therapeutic approaches are designed to slow disease progression, improve muscle function and enhance the overall quality of life for individuals with duchenne muscular dystrophy. For further insights on the Duchenne Muscular Dystrophy (DMD) Therapeutics market, request a sample here

How will the Duchenne Muscular Dystrophy (DMD) Therapeutics market drivers and restraints affect the market dynamics? What forces will shape the Duchenne Muscular Dystrophy (DMD) Therapeutics industry going forward?

The Duchenne Muscular Dystrophy (DMD) Therapeutics market major growth driver - Increasing Clinical Trials Revolutionize The Duchenne Muscular Dystrophy (DMD) Therapeutics Market. For further insights on the Duchenne Muscular Dystrophy (DMD) Therapeutics request a sample here

What is the forecast market size or the forecast market value of the Duchenne Muscular Dystrophy (DMD) Therapeutics market?

The Duchenne Muscular Dystrophy (DMD) Therapeutics market size has grown strongly in recent years. The duchenne muscular dystrophy (DMD) therapeutics market size has grown exponentially in recent years. It will grow from $11.95 billion in 2024 to $16.45 billion in 2025 at a compound annual growth rate (CAGR) of 37.6%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, awareness about duchenne muscular dystrophy treatment, rising healthcare spending, government initiatives. The duchenne muscular dystrophy (DMD) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $47.34 billion in 2029 at a compound annual growth rate (CAGR) of 30.3%. The growth in the forecast period can be attributed to growing investments in for duchenne muscular dystrophy treatments, adoption of combination therapies, emergence of biomarker,growing number of screening programs for duchenne muscular dystrophy. Major trends in the forecast period include innovative treatments for duchenne muscular dystrophy, development of targeted therapies, introduction of novel medications and therapies, innovative disease-modifying therapies, active drug developments. For further insights on the Duchenne Muscular Dystrophy (DMD) Therapeutics market, request a sample here

How is the Duchenne Muscular Dystrophy (DMD) Therapeutics market segmented?

The duchenne muscular dystrophy (DMD) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies For further insights on the Duchenne Muscular Dystrophy (DMD) Therapeutics market,
request a sample here

Which region has the largest share of the Duchenne Muscular Dystrophy (DMD) Therapeutics market? What are the other regions covered in the report?

North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. For further insights on the Duchenne Muscular Dystrophy (DMD) Therapeutics market, request a sample here.

Who are the major players in the Duchenne Muscular Dystrophy (DMD) Therapeutics market?

Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.. For further insights on the Duchenne Muscular Dystrophy (DMD) Therapeutics market, request a sample here.

What are the key trends in the Duchenne Muscular Dystrophy (DMD) Therapeutics market?

Major trends in the Duchenne Muscular Dystrophy (DMD) Therapeutics market include Bit Bio Leads Technological Advancements In Duchenne Muscular Dystrophy (DMD) Therapeutics. For further insights on the Duchenne Muscular Dystrophy (DMD) Therapeutics market request a sample here.

What are the major opportunities in the Duchenne Muscular Dystrophy (DMD) Therapeutics market? What are the strategies for the Duchenne Muscular Dystrophy (DMD) Therapeutics market?

For detailed insights on the major opportunities and strategies in the Duchenne Muscular Dystrophy (DMD) Therapeutics market, request a sample here.

How does the Duchenne Muscular Dystrophy (DMD) Therapeutics market relate to the overall economy and other similar markets?

For detailed insights on Duchenne Muscular Dystrophy (DMD) Therapeutics's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Duchenne Muscular Dystrophy (DMD) Therapeutics industry?

For detailed insights on the mergers and acquisitions in the Duchenne Muscular Dystrophy (DMD) Therapeutics industry, request a sample here.

What are the key dynamics influencing the Duchenne Muscular Dystrophy (DMD) Therapeutics market growth? SWOT analysis of the Duchenne Muscular Dystrophy (DMD) Therapeutics market.

For detailed insights on the key dynamics influencing the Duchenne Muscular Dystrophy (DMD) Therapeutics market growth and SWOT analysis of the Duchenne Muscular Dystrophy (DMD) Therapeutics industry, request a sample here.